| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Parecoxib (SC69124A; Dynastat) is a selective cyclooxygenase-2 (COX-2) inhibitor with the potential for treating postoperative pain in adults. It is a water-soluble and injectable prodrug of valdecoxib.
| ln Vitro |
Parecoxib (0-200 μM; 24-48 hours) reduces the growth of GBM cells in a dose-dependent manner [4]. Parecoxib (200 μM; 24-48 hours) caused the migratory ability of U343 cells to be reduced compared with the PBS-treated group [4].
|
|---|---|
| ln Vivo |
In the elevated plus maze test, parecoxib (ip; 2.5, 5.0, or 10 mg/kg; once daily; 21 days) had no effect on locomotor activity; however, the percentage of time spent with arms outstretched was higher for parecoxib at doses of 5 and 10 mg/kg[3].
|
| Cell Assay |
Cell Viability Assay [4]
Cell Types: GBM Cells: U251 and U343 Cell Tested Concentrations: 0 μM, 20 μM, 50 μM, 100 μM and 200 μM Incubation Duration: 24-48 hrs (hours) Experimental Results: Result in slower BrdU incorporation into GBM Cells include U251 and U343 cells. |
| Animal Protocol |
Animal/Disease Models: Adult male ICR mouse, 15 weeks old, weighing 25-35 grams [3]
Doses: 2.5, 5.0 or 10 mg/kg Route of Administration: intraperitoneal (ip) injection; 2.5, 5.0 or 10 mg/kg; one time/day; 21-day Experimental Results: Anxiolytic-like effects in the elevated plus maze test |
| References |
[1]. Jun Tang, et al. Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology
[2]. J L Mateos, et al.[Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review]. Drugs Today (Barc). 2010 Feb;46 Suppl A:1-25. [3]. Bo Wang, et al. Chronic administration of parecoxib exerts anxiolytic-like and memory enhancing effects and modulates synaptophysin expression in mice. BMC Anesthesiol. 2017 Nov 13;17(1):152. [4]. Lin-Yong Li, et al. Parecoxib inhibits glioblastoma cell proliferation, migration and invasion by upregulating miRNA-29c. Biol Open. 2017 Mar 15;6(3):311-316. |
| Molecular Formula |
C19H18N2O4S
|
|---|---|
| Molecular Weight |
370.42222
|
| CAS # |
198470-84-7
|
| Related CAS # |
Parecoxib Sodium;198470-85-8;Parecoxib-d3
|
| SMILES |
CCC(NS(=O)(C1=CC=C(C2=C(C)ON=C2C3=CC=CC=C3)C=C1)=O)=O
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~134.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6996 mL | 13.4982 mL | 26.9964 mL | |
| 5 mM | 0.5399 mL | 2.6996 mL | 5.3993 mL | |
| 10 mM | 0.2700 mL | 1.3498 mL | 2.6996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
